[{"address1": "15 Crosby Drive", "city": "Bedford", "state": "MA", "zip": "01730", "country": "United States", "phone": "781 357 4000", "fax": "781 275 7562", "website": "https://www.ocutx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.", "fullTimeEmployees": 267, "companyOfficers": [{"maxAge": 1, "name": "Mr. Donald  Notman Jr.", "title": "Chief Financial Officer", "fiscalYear": 2023, "totalPay": 679770, "exercisedValue": 0, "unexercisedValue": 90888}, {"maxAge": 1, "name": "Dr. Jeffrey S. Heier M.D.", "age": 62, "title": "Chief Scientific Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 86162, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rabia Gurses Ozden M.D.", "age": 54, "title": "Chief Medical Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 687349, "exercisedValue": 0, "unexercisedValue": 38971}, {"maxAge": 1, "name": "Dr. Pravin U. Dugel M.D.", "age": 59, "title": "Executive Chairman, President & CEO", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Karen-Leigh  Edwards M.B.A., Ph.D.", "title": "Chief Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter K. Jarrett Ph.D.", "age": 66, "title": "Chief Technology Officer", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William S. Slattery Jr.", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Philip C. Strassburger Esq.", "age": 63, "title": "General Counsel", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 282613, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William H. Ransone II", "title": "Vice President of Global Sales & Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tracy  Smith", "title": "Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 9, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.17, "open": 5.972, "dayLow": 5.57, "dayHigh": 6.305, "regularMarketPreviousClose": 6.17, "regularMarketOpen": 5.972, "regularMarketDayLow": 5.57, "regularMarketDayHigh": 6.305, "beta": 1.322, "forwardPE": -6.5909095, "volume": 5656458, "regularMarketVolume": 5656458, "averageVolume": 2718318, "averageVolume10days": 3552270, "averageDailyVolume10Day": 3552270, "bid": 5.79, "ask": 5.82, "bidSize": 1600, "askSize": 800, "marketCap": 897410816, "fiftyTwoWeekLow": 1.995, "fiftyTwoWeekHigh": 11.31, "priceToSalesTrailing12Months": 15.355317, "fiftyDayAverage": 8.2765, "twoHundredDayAverage": 4.93375, "currency": "USD", "enterpriseValue": 749621120, "profitMargins": -1.38145, "floatShares": 129225613, "sharesOutstanding": 154726000, "sharesShort": 14646476, "sharesShortPriorMonth": 9163734, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0947, "heldPercentInsiders": 0.00923, "heldPercentInstitutions": 0.56955004, "shortRatio": 8.0, "shortPercentOfFloat": 0.095, "impliedSharesOutstanding": 164314000, "bookValue": 0.793, "priceToBook": 7.3139977, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -80736000, "trailingEps": -1.02, "forwardEps": -0.88, "enterpriseToRevenue": 12.827, "enterpriseToEbitda": -9.441, "52WeekChange": -0.058015287, "SandP52WeekChange": 0.24486005, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "OCUL", "underlyingSymbol": "OCUL", "shortName": "Ocular Therapeutix, Inc.", "longName": "Ocular Therapeutix, Inc.", "firstTradeDateEpochUtc": 1406295000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b2e86f5b-6ae3-30af-bdc2-4b9ad5a2cf9e", "messageBoardId": "finmb_41955650", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.8, "targetHighPrice": 24.0, "targetLowPrice": 11.0, "targetMeanPrice": 15.5, "targetMedianPrice": 15.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 195807008, "totalCashPerShare": 1.317, "ebitda": -79399000, "totalDebt": 83389000, "quickRatio": 6.361, "currentRatio": 6.655, "totalRevenue": 58443000, "debtToEquity": 91.505, "revenuePerShare": 0.732, "returnOnAssets": -0.25658, "returnOnEquity": -1.27636, "freeCashflow": -49441000, "operatingCashflow": -70234000, "revenueGrowth": 0.052, "grossMargins": -0.13505, "ebitdaMargins": -1.35857, "operatingMargins": -1.35464, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-07"}]